Figure 2. Science growing into applications. Insight in IgG4 biology and the unraveling of the IgG4 Fab-arm exchange process formed the roots for 3 major branches of research that led to the generation of scientific papers and intellectual property through various industry-academia collaborations. These culminated in 3 novel antibody technology platforms for the generation of stabilized IgG4, stable IgG4 half molecules (UniBody®) and bispecific IgG1 (DuoBody®). Numbers indicate: the number of collaborating parties involved; the number of patent applications filed26,27,29-35,38-41,52; the number of scientific papers published20-25,36,37,53-62; and the number of platform licensees that occurred between 2003 (the beginning of the IgG4 project within Genmab) and April 2014. Source: Joost Bakker (Scicomvisuals).